Gilead to buy CymaBay Therapeutics for $4.3B

California-based pharmaceutical giant Gilead Sciences disclosed on Monday that it will acquire CymaBay Therapeutics Inc. for an estimated $4.3 billion or $32.50 per share. The transaction is anticipat…